Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Receivables - Accured (2018 - 2022)

Abvc Biopharma (ABVC) has disclosed Revenue - Other for 5 consecutive years, with -$7769.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Revenue - Other fell 1682.28% year-over-year to -$7769.0, compared with a TTM value of $34058.0 through Sep 2023, up 121.14%, and an annual FY2022 reading of -$24149.0, down 207.76% over the prior year.
  • Receivables - Accured was $81404.0 for Q3 2022 at Abvc Biopharma, up from $2325.0 in the prior quarter.
  • Across five years, Receivables - Accured topped out at $81404.0 in Q3 2022 and bottomed at $1302.0 in Q4 2020.
  • Average Receivables - Accured over 4 years is $28124.5, with a median of $14896.0 recorded in 2018.
  • Peak annual rise in Revenue - Other hit 221.53% in 2022, while the deepest fall reached 31249.38% in 2022.
  • Year by year, Revenue - Other stood at -$101749.0 in 2021, then soared by 134.63% to $35232.0 in 2022, then crashed by 122.05% to -$7769.0 in 2023.
  • Business Quant data shows Revenue - Other for ABVC at -$7769.0 in Q3 2023, $3528.0 in Q2 2023, and $3067.0 in Q1 2023.